

Practical Gynecology, 2nd Edition – Chapter 4 References

- *1. **Janiger O, Riffenburgh R, Kersh R.** Cross-cultural study of premenstrual symptoms. *Psychosomatics*. 1972;13:226-35.
2. **Wittchen HU, Becker E, Lieb R, Krause P.** Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. *Psychol Med*. 2002 Jan;32(1):119-32.
- *3. **American Psychiatric Association.** Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC; 1994.
4. **Morgan M, Rapkin AJ, D'Elia L, Reading A, Goldman L.** Cognitive functioning in premenstrual syndrome. *Obstet Gynecol*. 1996;Dec;88(6):961-6.
5. **ACOG committee opinion: premenstrual syndrome.** No. 155, April 1995 (Replaces No. 66, January 1989). *Int J Gynecol Obst*. 1995;50:80-4.
6. **Freeman EW, Rickels K, Schweizer E, Ting T.** Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. *Psychol Med*. 1995;25:309-15.
7. **Pearlstein T, Steiner M.** Non-antidepressant treatment of premenstrual syndrome. *J Clin Psychiatry*. 2000;61 Suppl 12:22-7. Review.
- *8. **Campagne DM, Campagne G.** The premenstrual syndrome revisited. *Eur J Obstet Gynecol Reprod Biol*. 2007;Jan;130(1):4-17.
9. **Rubinow DDR, Schmidt PJ.** Premenstrual syndrome: a review of endocrine studies. *Endocrinology*. 1992;2:47-54.
10. **Hammarback S, Elkhalm UB, Backstrom T.** Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. *Acta Endocrinol*. 1991;124:132-7.
11. **Casson P, Hahn PM, VanVugt DA, Reid RL.** Lasting response to ovariectomy in severe intractable premenstrual syndrome. *Am J Obstet Gynecol*. 1990;162:99-105.
12. **Rubinow D.** The premenstrual syndrome: new views. *JAMA*. 1992;268:1908-12.
- *13. **Condon, JT.** The premenstrual syndrome: a twin study. *Br J Psychiatry*. 1993;162:481-6.
- *14. **Hausfater G, Skoblick B.** Premenstrual behavior changes among female yellow baboons: some similarities to premenstrual syndrome (PMS) in women. *Am J Primatol*. 1985;9:165-72.
15. **Rowell TE.** Behavior and female reproductive cycles of rhesus macaques. *J Reprod Fertil*. 1963;6:193-203.

- *16. **Graham CA, Sherwin BB.** A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. *J Psychosomatic Res.* 1992;36:257-66.
- *17. **Hammarback S, Backstrom T, Holst J, et al.** Cyclical mood changes in the premenstrual tension syndrome during sequential estrogen-progestagen post-menopause replacement therapy. *Acta Obstet Gynecol Scand.* 1985;64:393-7.
- *18. **Rapkin AJ, Morgan M, Goldman L, et al.** Progesterone metabolite allopregnanolone in women with premenstrual syndrome. *Obstet Gynecol* 1997;90:709-14.
19. **Monteleone P, Luisi S, Tonetti A, et al.** Allopregnanolone concentrations and premenstrual syndrome. *Eur J Endocrin.* 2000;142:269-73.
20. **Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB.** Progesterone metabolite allopregnanolone in women with premenstrual syndrome. *Obstet Gynecol.* 1997; Nov;90(5):709-14.
21. **Thys-Jacobs S, Alvir MJ.** Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. *J Clin Endocrinol Metab.* 1995; Jul;80(7):2227-32
- *22. **Thys-Jacobs S, Silverton M, Alvir J, et al.** Reduced bone mass in women with premenstrual syndrome. *J Womens Health.* 1995;4:161-8.
- *23. **Indusekhar R, Usman SB, O'Brien S.** Psychological aspects of premenstrual syndrome. *Best Pract Res Clin Obstet Gynaecol.* 2007; Apr;21(2):207-20. Review. *This paper is an excellent overview of the premenstrual syndrome, and includes a fascinating summary of premenstrual behavior changes.*
24. **Ashby CR, Carr LA, Cook CL, et al.** Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. *Biol Psychiatry.* 1988;24: 225-33.
- *25. **Rapkin AJ, Edelmuth E, Chang LC, et al.** Whole-blood serotonin in premenstrual syndrome. *Obstet Gynecol.* 1987;70:533-7.
26. **Rapkin A.** A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. *Psychoneuroendocrin* 2003;28 Suppl 3:39-53.
- *27. **Amin Z, Mason GF, Cavus I, Krystal JH, Rothman DL, Epperson CN.** The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. *Pharmacol Biochem Behav.* 2006 Aug;84(4):635-43. Epub 2006 Jul 24. Review. *This paper discusses the complex interplay of estradiol, progesterone and allopregnanolone with gamma aminobutyric acid (GABA) in the brain, including the likely mechanism through which PMS symptoms are generated.*

28. **Chuong CJ, Bartholomew PH, Gibbons WE.** Periovulatory beta-endorphin levels in premenstrual syndrome. *Obstet Gynecol.* 1994;83:755-60.
29. **Chuong CJ, Coulam CB, Kao PC, et al.** Neuropeptide levels in premenstrual syndrome. *Fertil Steril.* 1985;44:760-5.
- *30. **Halbreich U, Petty F, Yonkers K, et al.** Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. *Am J Psychiatry.* 1996;153:718-20.
- *31. **Rapkin AJ, Chang LC, Reading AE.** Comparison of retrospective and prospective assessment of premenstrual symptoms. *Psychol Rep.* 1988 Feb;62(1):55-60.
- *32. **Case AM, Reid RL.** Effects of the menstrual cycle on medical disorders. *Arch Intern Med.* 1998;158:1405-12.
33. **National Institute of Mental Health.** Premenstrual Syndrome Workshop Guidelines. Rockville, MD; 1983.
34. **Pearlstein T.** Nonpharmacologic treatment of premenstrual syndrome. *Psychiatric Annal.* 1996;26:9:590-4.
- *35. **Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J.** Calcium supplementation in premenstrual syndrome: a randomized crossover trial. *J Gen Intern Med.* 1989 May-Jun;4(3):183-9.
36. **Thys-Jacobs S, Starkey P, Bernstein D, Tian J.** Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. *Am J Obstet Gynecol.* 1998; Aug;179(2):444-52.
37. **Sayegh R, Schiff I, Wurtman J, et al.** The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. *Ob-stet Gynecol.* 1995;86:520-8.
- *38. **Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K.** Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. *J Womens Health (Larchmt).* 2006 Jan-Feb;15(1):57-69. Review.
39. **Su T-P, Schmidt PJ, Danaceau MA, et al.** Fluoxetine in the treatment of premenstrual dysphoria. *Neuropsychopharmacology.* 1997;16:5:346-56.
- *40. **Stone AB, Pearlstein TB, Brown WA.** Fluoxetine in the treatment of late luteal phase dysphoric disorder. *J Clin Psychiatry.* 1991;52:7:290-3. *Although very small, this randomized placebo-controlled trial is a landmark study as it uncovered a drug whose class quickly became established as the most effective treatment for PMS.*

41. **Menkes DB, Taghavi E, Mason PA, Howard RC.** Fluoxetine's spectrum of action in premenstrual syndrome. *Int Clin Psychopharmacol.* 1993;8:95-102.
42. **Wood SH, Mortola JF, Chan Y-F, et al.** Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. *Obstet Gynecol.* 1992;80:3:339-44.
43. **Pearlstein TB, Stone AB.** Long-term fluoxetine treatment in late luteal phase dysphoric disorder. *J Clin Psychiatry.* 1994;55:332-5.
44. **Steiner M, Steinberg S, Steward D, et al.** Fluoxetine in the treatment of premenstrual dysphoria. *N Engl J Med.* 1995;332:1529-34.
45. **Landén M, Nissbrandt H, Allgulander C, Sörvik K, Ysander C, Eriksson E.** Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. *Neuropsychopharmacology.* 2007;Jan;32(1):153-61.
46. **Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M.** Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. *Psychosom Med.* 2004;Sep-Oct;66(5):707-13.
47. **Steiner M, Hirschberg AL, Bergeron R et al.** Luteal phase dosing with paroxetine controlled release in the treatment of premenstrual dysphoric disorder. *Am J Obstet Gynecol.* 2005;193:352-360.
- *48. **Halbreich U, Smoller JW.** Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. *J Clin Psychiatry.* 1997 Sep;58(9):399-402.
- *49. **Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA.** Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. *J Clin Psychiatry.* 2006 Oct;67(10):1624-32. *This multi-center study examined low-dose sertraline in three different dosing strategies: luteal phase treatment, continuous dosing throughout the month, and symptom-onset dosing. All three strategies were found to be effective in treating PMS symptoms.*
50. **Freeman EW, Jabara S, Sondheimer SJ, Auletto R.** Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. *J Womens Health Gen Based Med.* 2002; Jun;11(5):459-64.
51. **Dimmock PW, Wyatt KM, Jones PW, O'Brien PM.** Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. *Lancet.* 2000;Sep 30;356(9236):1131-6.
52. **Pinna G, Costa E, Guidotti A.** Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. *Psychopharmacology (Berl).* 2006;186;3:362-72.
53. **Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, Eriksson E.** Citalopram in premenstrual dysphoria: is intermittent treatment during luteal

phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;Oct;18(5):390-8.

54. **Steiner M, Korzekwa M, Lamont J, Wilkins A.** Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharm Bull. 1997;33: 771-4.

*55. **Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA.** Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord 2005;85;3:317-21.

*56. **Yonkers KA, Holthausen GA, Poschman K, Howell HB.** Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006 Apr;26(2):198-202.

57. **Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H.** A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry. 2005 Jun;66(6):769-73.

58. **Kahn LS, Halbreich U.** Oral contraceptives and mood. Exper Opin Pharmacother 2001;2:1367-1382.

59. **Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M; PMS/PMDD Research Group.** Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gen Based Med. 2001 Jul-Aug;10(6):561-9.

*60. **Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA.** Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72;6:414-421. *This is the first placebo-controlled trial demonstrating the effectiveness of an oral contraceptive in treating PMS. The contraceptive (Yasmin) is unique for two reasons: it contains the spironolactone-like progestin drospirenone and has a shortened pill-free interval of only 4 days.*

61. **Graham CA, Sherwin BB.** A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-266.

62. **Hammarback S, Backstrom T.** Induced anovulation as treatment of the premenstrual tension syndrome: a double-blind crossover study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand. 1988;67:159-66.

63. **Watts JFF, Butt WR, Edwards RL.** A clinical trial danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol. 1987;94:30-4.

64. **Watson N, Studd J, Savvas M, Baber RJ.** The long-term effect of oestradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol. 1990;4:99:107.

65. **Smith S, Rinehart JS, Ruddock VE, Schiff I.** Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. *Obstet Gynecol.* 1987;70:37-43.
66. **Wang M, Hammarback S, Lindhe BA, Backstrom T.** Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. *Acta Obstet Gynecol Scand.* 1995;74:10:803-8.
67. **Fruzzetti F, Lazzarini V, Ricci C, Quirici B, Gambacciani M et al.** Effect of an oral contraceptive containing 30 mcg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. *Contraception.* 2007;76;3:190-4.
- *68. **Parry BL, Cover C, Mostofi N, et al.** Early vs. late partial sleep deprivation in patients with premenstrual dysphoric disorder and normal comparison subjects. *Am J Psychiatry.* 1995;152:404-12.
69. **Budeiri D, Li Wan Po A, Dornan JC.** Is evening primrose oil of value in the treatment of premenstrual syndrome? *Control Clin Trials.* 1996 Feb;17(1):60-8.
70. Wyatt KM, Kimmock PW, Jones PW, O'Brien PM. Efficacy of vitamin B₆ in the treatment of premenstrual syndrome: systemic review. *BMJ.* 1999;318:1375-81.